The interleukin‐17 pathway is involved in human alcoholic liver disease

Arnaud Lemmers, Christophe Moreno, Thierry Gustot, Raphaël Maréchal, Delphine Degré, Pieter Demetter, Patricia de Nadai, Albert Geerts, Eric Quertinmont, Vincent Vercruysse, Olivier Le Moine, Jacques Devière – 28 January 2009 – Immune dysregulations in alcoholic liver diseases are still unclear, especially regarding alcoholic hepatitis inflammatory burst. Interleukin‐17 (IL‐17) is known to enhance neutrophil recruitment. We studied the IL‐17 pathway in alcoholic cirrhosis and alcoholic hepatitis.

Determinants of relapse after a short (12 weeks) course of antiviral therapy and re‐treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection

Alessandra Mangia, Nicola Minerva, Donato Bacca, Raffaele Cozzolongo, Ernesto Agostinacchio, Fernando Sogari, Gaetano Scotto, Francesco Vinelli, Giovanni Luciano Ricci, Mario Romano, Vito Carretta, Daniela Petruzzellis, Angelo Andriulli – 28 January 2009 – In hepatitis C virus (HCV) genotypes 2 and 3 patients, the high rate of relapse after 12 to 16 weeks of antiviral therapy is the main concern for shortening treatment duration.

Should liver transplantation in patients with model for end‐stage liver disease scores ≤ 14 be avoided? A decision analysis approach

James D. Perkins, Jeffrey B. Halldorson, Ramasamy Bakthavatsalam, Oren K. Fix, Robert L. Carithers, Jorge D. Reyes – 28 January 2009 – Studies have shown that liver transplantation offers no survival benefits to patients with Model for End‐Stage Liver Disease (MELD) scores ≤ 14 in comparison with remaining on the waitlist. The consensus of a 2003 transplant community national conference was that a minimum MELD score should be required for placement on the liver waitlist, but no minimum listing national policy was enacted at that time.

Pediatric liver retransplantation: Outcomes and a prognostic scoring tool

Adam Davis, Philip Rosenthal, David Glidden – 28 January 2009 – Nine to twenty‐nine percent of pediatric liver transplant recipients require retransplantation. No previous pediatric study has proposed a prognostic scoring system. We have used the United Network for Organ Sharing transplantation database to conduct a retrospective cohort study of patients who were less than 18 years of age when they received their retransplant (n = 1130).

Subscribe to